About 0.04% people tested positive after second dose of Covaxin, 0.03% for Covishield: Government
India has currently given Emergency Use Authorisation to three vaccine candidates: indigenously manufactured vaccines (Serum Institute of India and Bharat Biotech), and a third vaccine (Sputnik) that while presently manufactured abroad will eventually be manufactured in India.
The Union Health Ministry Wednesday said about 0.04% people tested positive after the second dose of Covaxin and 0.03% after the second dose of Covishield.
India has currently given Emergency Use Authorisation to three vaccine candidates: indigenously manufactured vaccines (Serum Institute of India and Bharat Biotech), and a third vaccine (Sputnik) that while presently manufactured abroad will eventually be manufactured in India.
The ministry also said that those below 10 years of age, 4.03% Covid-19 cases were reported in the first wave, while 2.97% cases registered in the second wave.
In the age group 10-20 years, 8.07% Covid-19 cases were reported in the first wave, while 8.50% cases were registered in the second wave.
In the age group 20-30 years, 20.41% Covid-19 cases were reported in the first wave, while 19.35% cases registered in the second wave.
In those aged 30 and above, 67.5% Covid-19 cases were reported in the first wave, while 69.18% cases registered in the second wave.
Reviewing the Covid-19 situation in the country, the health secretary Rajesh Bhushan said, "There are 21,57,000 active cases in India currently i.e. twice the number of maximum active Covid-19 cases last year. More than 13 crore people have been vaccinated in the country so far including 30 lakh doses administered in the last 24 hours."
On Monday, the Centre also announced a "liberalised and accelerated" Phase 3 strategy of Covid-19 vaccination from May 1 in order to ramp up the coronavirus vaccination drive in the country.
Everyone above the age of 18 to be eligible to get Covid-19 vaccine, said the government.